SEC Tracker
Get the app
CTKB · XBRL financial data

Cytek Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CTKB's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue48,00058,233*44,86046,61751,500———————
Revenue from contracts with customers48,00058,233*44,86046,61751,50057,476*41,45745,60252,29362,141*44,13548,140
Cost of goods and services sold20,82225,185*21,84721,18122,49523,824*21,30021,73524,74229,256*22,88119,800
Gross profit27,17833,048*23,01325,43629,00533,652*20,15723,86727,55132,885*21,25428,340
Research and development11,17110,869*9,79610,0019,8829,723*9,7258,8268,9568,962*9,6049,741
General and administrative10,35110,755*11,40811,69410,9429,069*12,89813,53116,12116,386*18,46716,825
Total operating expenses33,59833,185*33,74733,96333,25330,666*35,13234,49136,74338,479*39,71739,740
Operating income (loss)(6,420)(137)*(10,734)(8,527)(4,248)2,986*(14,975)(10,624)(9,192)(5,594)*(18,463)(11,400)
Interest income1,6221,448*1,3591,4161,433913*508555573580*787819
Interest expense595394*441134119(5,933)*291414494(725)*262281
Other income (expense)1,2083,194*823593,091491*3,4923,7081,344258*565(781)
Income tax expense (benefit)2,271(1,392)*(2,824)3,248(784)680*136(1,192)(2,291)40,045*1,493515
Net income (loss)—year only(6,169)——year only(11,402)(5,583)—year only(18,866)(12,158)
Weighted average shares, basic thousands of shares136,173133,562*130,921131,440131,004129,092*128,339126,934127,548128,166*128,705129,461
Weighted average shares, diluted thousands of shares136,173133,562*130,921131,440132,786127,311*128,339126,934127,548128,166*128,705129,461

Balance sheet

CSV

Fiscal quarters (CTKB's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents163,629167,299168,788177,888162,27298,71695,29975,47093,28190,85365,66573,846
Accounts receivable55,40255,92850,30644,64352,63460,58855,02956,23256,63262,50951,90349,698
Inventory66,87560,87754,74250,07046,80043,89345,34749,48751,64948,42849,79152,251
Prepaid and other current assets12,01712,51413,16012,13012,94914,07514,51215,08418,47419,53015,38313,978
Total current assets422,315392,060388,647384,084390,191396,446380,501382,825388,489391,996379,302377,931
Property and equipment, net17,41518,40518,24718,11418,50817,96217,83418,35218,04618,00920,46920,801
Right-of-use asset11,70310,8539,9499,32810,12410,1689,86916,38711,15811,31510,64310,962
Goodwill16,45716,18316,18316,18316,18316,66316,67816,70716,69816,69716,68916,690
Total assets519,430494,457492,067483,725491,226499,500482,596493,320494,919461,542449,113446,934
Accrued liabilities20,51420,03518,05415,48920,73321,44319,19721,60420,23323,41719,78123,855
Total current liabilities58,69356,22655,56652,37962,79767,66367,69173,27075,20777,80480,93584,335
Lease liability, non-current10,1399,4798,6978,1137,7567,5527,44814,11913,49414,04213,44113,517
Total liabilities103,906101,39399,45394,602105,763103,763102,973115,763116,348119,803121,469124,980
Accumulated deficit(34,681)(29,178)(35,347)(45,781)(44,840)(35,199)(46,601)(52,184)(57,662)(101,738)(120,604)(132,761)
Total stockholders' equity415,524393,064392,614389,123385,463395,737379,623377,557378,571341,739327,644321,954
Total liabilities and equity519,430494,457492,067483,725491,226499,500482,596493,320494,919461,542449,113446,934
Common shares outstanding (cover page) thousands of shares135,549130,824131,273131,506128,811128,097126,659127,224127,865128,550129,143129,983

Cash flows

CSV

Fiscal quarters (CTKB's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)—year only(6,169)——year only(11,402)(5,583)—year only(18,866)(12,158)
Stock-based compensation5,758*5,669*5,6407,152*7,053*7,003*6,6306,790*5,638*5,527*4,8615,339*
Depreciation and amortization1,767*1,631*1,6991,808*1,851*1,854*1,8751,890*1,918*1,896*1,8652,009*
Net cash from operating activities(4,239)*9,512*3,9576,204*13,221*1,997*(125)108*(3,898)*(771)*(2,736)1,367*
Purchases of property and equipment1,330*1,500*5671,053*1,011*894*8491,577*657*1,001*2,1682,216*
Net cash from investing activities43,124*29,066*(5,754)2,022*(15,809)*(63,433)*9,452(16,413)*18,920*(1,842)*(27,079)7,022*
Share repurchases—34,60002,70011,9007,00010,6274,510*(29)*(34)*00*
Net cash from financing activities(8,274)*(33,754)*1,613(1,711)*(12,084)*(3,640)*(11,545)(2,602)*1,941*(1,226)*3,981(814)*
Net change in cash32,085*4,001*1,5118,777*(15,615)*(63,558)*(3,446)(19,829)*17,810*(2,427)*(25,188)8,181*

Compare with peers

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cytek Biosciences73,84648,1401,367*130.0M— 10-QJun 30, 2026
Crawford United1,923not reported5,706*not reported— 10-QSep 30, 2025
Senseonics Holdings44,75314,483(30,138)*52.9M4.7 quarters 10-QJun 30, 2026
Pacific Biosciences of California61,00339,007(35,583)*310.8M6.7 quarters 10-QJun 30, 2026
Mesa Laboratories30,69560,13814,7365.6M— 10-QJun 30, 2026
Allient42,088153,77013,954*17.0M— 10-QJun 30, 2026
Quantum-Si23,653344(18,444)*not reported6.1 quarters 10-QJun 30, 2026
Frequency Electronics61,40723,4512,62211.3M— 10-QJul 31, 2026
EyePoint110,458507(62,348)*86.2M2.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.